BP
BigPeptideList

Tesamorelin

FDA Approved

Growth Hormone Secretagogues · GHRH Analog

Tesamorelin is an FDA-approved GHRH analog originally indicated for reducing excess abdominal fat in HIV-associated lipodystrophy.

What is Tesamorelin?

Tesamorelin is an FDA-approved GHRH analog originally indicated for reducing excess abdominal fat in HIV-associated lipodystrophy. It is increasingly used off-label in anti-aging medicine for its ability to stimulate natural growth hormone production and reduce visceral fat.

Also known as: TH9507

How Does Tesamorelin Work?

Binds to pituitary GHRH receptors, stimulating physiological growth hormone secretion. Specifically reduces visceral adipose tissue through GH-mediated lipolysis. Improves trunk fat, lipid profiles, and IGF-1 levels.

What is Tesamorelin Used For?

  • Visceral fat reduction
  • HIV lipodystrophy
  • Growth hormone optimization

Potential Side Effects

  • Injection site reactions
  • Joint pain
  • Peripheral edema
  • Paresthesia

Contraindications

  • Active malignancy
  • Pituitary surgery
  • Pregnancy

FDA Legal Status

United States — FDA

FDA Approved

This peptide requires a prescription from a licensed healthcare provider.

Related Peptides

Sermorelin

Compoundable (Rx)

Growth Hormone Secretagogues

Sermorelin is a synthetic analog of the first 29 amino acids of natural growth hormone-releasing hormone (GHRH). It was ...

CJC-1295

Compoundable (Rx)

Growth Hormone Secretagogues

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates sustained growth hormone relea...

Ipamorelin

Compoundable (Rx)

Growth Hormone Secretagogues

Ipamorelin is a selective growth hormone secretagogue that stimulates the pituitary gland to produce growth hormone with...

Frequently Asked Questions

Is tesamorelin FDA-approved?
Yes. Tesamorelin (Egrifta) is FDA-approved specifically for reducing excess abdominal fat in HIV-infected patients with lipodystrophy. It is also used off-label for anti-aging and growth hormone optimization.

Quick Facts

Legal Status (USA)
FDA Approved
Evidence Rating
AStrong Evidence (Multiple RCTs)
Class / Subclass
Growth Hormone Secretagogues / GHRH Analog
Administration
subcutaneous
Typical Dosage
2mg daily
Half-Life
26-38 minutes
Brand Names
Egrifta
Year Discovered
2001
Approval Year
2010

Sources

PubMed 17973856

Last updated: 2026-04-01

Sources & references

Primary sources used for the dosing, mechanism, side-effect, and regulatory claims on this page. Verify time-sensitive information (regulatory status, prescribing details) on the source before relying on it for medical decisions. See our disclaimer.

  1. PubMed PMID 17973856 — peer-reviewed primary literature on Tesamorelin.
  2. FDA Drugs@FDA database — search for the current FDA-approved label, indications, and prescribing information for Tesamorelin.
  3. FDA Federal Register — official notice record for FDA regulatory actions and Category 1 / 503A bulk-substance updates.